Mixed Hyperlipidemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for mixed hyperlipidemia. 24 active patents protecting 4 drugs from 3+ originators. First major cliff: 2037. Daily refresh.

4
Approved drugs
24
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered

Originators in Mixed Hyperlipidemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 18 patents Pfizer 5 patents Salix 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating mixed hyperlipidemia. Each bar = one year. Y-axis scaled to peak year (9 patents).

6
26
2
27
2
30
9
33
5
37

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zocor
simvastatin
 Merck & Co. 10 70 — 2026-10-11
Zetia
EZETIMIBE
 Merck & Co. 8 63 — 2033-05-01
Lipitor
Atorvastatin Calcium
 Pfizer 5 61 — 2037-06-07
Tricor (Micronized)
FENOFIBRATE
 Salix 1 62 — 2033-05-31

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
7326708 Zocor other 80 2026-10-11
11925704 Lipitor method of use 75 2037-06-07
11654106 Lipitor method of use 70 2037-06-07
9763885 Zetia method of use 62 2033-05-01
10376470 Zetia method of use 62 2033-05-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9597289 Zocor formulation 48 2030-02-23
9597289 Zocor formulation 48 2030-02-23
11369567 Lipitor formulation 50 2037-06-07
12168069 Lipitor formulation 55 2037-06-07
12370136 Lipitor formulation 55 2037-06-07
10300041 Zocor formulation 60 2027-04-26
10300041 Zocor formulation 60 2027-04-26
9314447 Tricor (Micronized) method of use 62 2033-05-31
9763885 Zetia method of use 62 2033-05-01
10376470 Zetia method of use 62 2033-05-01

Related